BioSpace News Archive

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it has promoted John Hamm to Director Finance & Accounting and Chief Financial Officer .

Y-mAbs Therapeutics, Inc. announced that it has entered into an exclusive distribution agreement with Adium Pharma S.A. to be the exclusive distributor in Latin America of the Company’s antibodies, DANYELZA® for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.

Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington’s disease and maximizing opportunities created by TRACERTM gene therapy technology platform and next-generation targeted AAV capsids

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has commenced an underwritten public offering of shares of common stock.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021.

Donations to be Distributed through C.H. Robinson to Health Systems and Key Areas by Direct Relief, Heart to Heart International, IsraAid, MAP International, and Project HOPE

Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions

Sensei Biotherapeutics, a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced new data from the ongoing Phase 1/2 clinical trial of SNS-301, an investigational medicine in patients with advanced squamous cell carcinoma of the head and neck, in combination with pembrolizumab.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced preliminary safety and anti-tumor activity data from the Company’s ongoing Phase 1 clinical trial of MGC018.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology Annual Meeting beginning on June 4,2021.